In the news


Most Read

  • ADNA launches in Cape Town
    Creative intelligence group, ADNA (Audience DNA) is expanding into Africa with their new regional headquarters in Cape Town. The agency officially launched here in January this year with a full-service team including data, creative and strategic consultancy, consumer and market insights.
  • Nestlé Cremora remakes iconic 'it's not inside, it's on top' ad
    Much like its iconic advert 'it's not inside, it's on top' which portrayed an insightful observation of people's responses from all races, ages and genders; Nestlé Cremora, a local favourite coffee and tea creamer, remains an unforgettable brand, more so in light of its strong heritage with South African consumers.
  • Telkom announces a new CEO
    Telkom has announced that Serame Taukobong, the company's current CEO of the Telkom Consumer Business and a group executive committee member, has been appointed as its new group CEO, effective 1 October. Taukobong will take up the position on 1 July 2022.
  • Homegrown battery manufacturer secures R20m investment
    Boost for local champion bringing innovative, local and trusted battery storage solutions for African energy needs
    Issued by Edge Growth
  • RIP Cyril Vuyani Gamede
    The Construction Industry Development Board (CIDB) has announced the passing of its CEO, Cyril Vuyani Gamede, who died at the age of 58 on 1 August.
  • Net#work BBDO wins Budweiser, Stella Artois and Corona
    In a rough, tough time in our industry and country, Net#work BBDO has slowly been chipping away at new account wins as the agency forges forward, most recently adding the Budweiser, Stella Artois and Corona brands to their portfolio as creative lead partner.
Show more
Advertise on Bizcommunity

Subscribe to industry newsletters

Using nanomedicine to fight TB

Tuberculosis (TB) is one of the world's deadliest infectious diseases. It's massive, it's tricky, and treatment can be exhausting (and toxic). But there may be new hope for TB treatment on the horizon: nanomedicine.
Admire Dube, associate professor of pharmacy, University of the Western Cape
“Nanomedicine is the use of nanotechnology to either diagnose or treat a disease. By creating and manipulating structures in the nanometre size range, we can devise medical solutions that are limited only by our imaginations," says Admire Dube, associate professor of pharmacy at the University of the Western Cape (UWC).

The nanoparticles used in nanomedicine are about 800 times smaller than the thickness of human hair, can be loaded with a variety of types of drugs such as proteins, DNA or even extracts from plants, and can be administered into the human body through swallowing, inhaling, injections or via the skin.

“Typically, nanoparticles are packed with drugs, and can be designed to target only the site of the disease, and release the drug there. Multiple drugs can be loaded in a single or a mixture of nanoparticles, (each containing a single type of drug), can be administered into the body to target disease sites and deliver drugs to those sites," he says.

The power of nanoparticles

Nanoparticles are able to make the drugs more available for infection by protecting them from breakdown prior to reaching the site, where there’s a greater uptake of the nanoparticles. With better targeting, patients would need to take less medication for a shorter duration, with fewer side effects and less waste. And (hopefully) treatment would be cheaper.

“Nanomedicine is one of the most exciting applications of nanotechnology and promises to address several of mankind’s healthcare needs.”

There are currently about 50 nanomedicines worldwide which are in use by doctors to treat diseases - most of these for the treatment of cancers. Many researchers believe that nanomedicine could help TB patients enormously as well, and Dube’s research at UWC is focused on just that - examining the application of nanoparticles towards the treatment of TB, especially to achieve immunotherapy, targeted drug delivery and/or access across biological barriers.

“We engineer nanoparticles and use these to deliver high doses of drugs into macrophages,” he explains. “Since these are immune cells, we also engineer the nanoparticles to activate these macrophages (known as immunotherapy) and therefore we can deliver a double, lethal punch to Mycobacterium tuberculosis.”

This form of immunotherapy holds great promise: it could prevent the generation of drug-resistant TB strains since the body’s own immune system is used to kill the bacteria. And since nanomedicines can be inhaled, they can be localised in the lungs – the centre of TB infection.

“It’s hoped that these TB-specific nanomedicines will make it to human trials over the next few years, and that they will prove to be safe and effective – and start doing the important work of tackling this debilitating disease," Dube says.

A better, healthier world

Dube is one of many scientists exploring the potential of nanotechnology for a better world. He first became interested in nanomedicine when he read of the multitude of possibilities offered by nanotechnology for addressing health problems.

“Nanomedicine is a very exciting field from a technological perspective, and opens up many possibilities for innovation to address specific patient health needs. It also provides unique opportunities for scientists from different backgrounds to come and work together to solve medical problems, and such teams usually include pharmacists, medical doctors, biotechnologists, chemists, physicists and material scientists.”

“I have a strong desire to see the development of an effective nanomedicine therapy for persons suffering from tuberculosis in South Africa,” he says. “Nanomedicine offers multiple opportunities to develop such therapies - and really, one’s imagination is the limit.”

Let's do Biz